Hologic, Inc. (NASDAQ:HOLX) Shares Sold by GTS Securities LLC

GTS Securities LLC lessened its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 46.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,564 shares of the medical equipment provider's stock after selling 9,912 shares during the period. GTS Securities LLC's holdings in Hologic were worth $834,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of HOLX. Principal Financial Group Inc. raised its position in Hologic by 0.6% during the 4th quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock valued at $19,547,000 after purchasing an additional 1,606 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Hologic by 44.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 63,744 shares of the medical equipment provider's stock valued at $4,595,000 after buying an additional 19,688 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its holdings in shares of Hologic by 11.4% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 68,427 shares of the medical equipment provider's stock valued at $4,933,000 after acquiring an additional 6,986 shares in the last quarter. Groupama Asset Managment lifted its stake in Hologic by 63.4% in the fourth quarter. Groupama Asset Managment now owns 54,214 shares of the medical equipment provider's stock worth $3,918,000 after acquiring an additional 21,037 shares during the period. Finally, Olstein Capital Management L.P. lifted its stake in Hologic by 5.9% in the fourth quarter. Olstein Capital Management L.P. now owns 90,000 shares of the medical equipment provider's stock worth $6,488,000 after acquiring an additional 5,000 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.

Insider Buying and Selling

In other Hologic news, Director Martin D. Madaus purchased 5,445 shares of the stock in a transaction on Wednesday, May 7th. The shares were bought at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the acquisition, the director now owns 5,445 shares in the company, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.88% of the stock is currently owned by corporate insiders.

Hologic Stock Performance

Hologic stock traded down $0.79 during trading hours on Thursday, hitting $62.92. 3,662,161 shares of the stock traded hands, compared to its average volume of 3,115,470. The firm's 50 day moving average price is $58.09 and its 200-day moving average price is $66.21. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The stock has a market capitalization of $14.02 billion, a price-to-earnings ratio of 19.85, a P/E/G ratio of 2.14 and a beta of 0.54. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same quarter in the prior year, the firm earned $1.03 earnings per share. Hologic's revenue for the quarter was down 1.2% on a year-over-year basis. As a group, equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Wall Street Zen lowered shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Leerink Partners downgraded shares of Hologic from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. Royal Bank of Canada lowered their target price on Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a report on Friday, May 2nd. Citigroup cut their price target on Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Hologic in a research report on Tuesday. Twelve equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Hologic currently has a consensus rating of "Hold" and a consensus price target of $77.42.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.